Advertisement

Topics

Celltrion And Teva Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Herceptin(Trastuzumab)

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Celltrion And Teva Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Herceptin(Trastuzumab)

NEXT ARTICLE

More From BioPortfolio on "Celltrion And Teva Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Herceptin(Trastuzumab)"

Quick Search
Advertisement